Neurology · Port Charlotte, FL
NPI
1700847597
Since 2006
Specialty
Neurology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4235 Kings Hwy, Suite 102
Port Charlotte, FL, 33980
Phone (941) 743-4987
Groups this clinician bills Medicare through
Medicare paid, 2024
$244K
12,530 services
Medicare patients, 2024
331
Average age 78
Drug cost, 2024
$3.9M
2,553 prescriptions
Company payments, 2025
$85K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ramon A Gil was code J0586 (injection, abobotulinumtoxina, 5 units), 4,760 times for 15 patients. In total Ramon A Gil billed 12,530 services in 36 codes, and Medicare paid $244K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0586 Injection, abobotulinumtoxina, 5 units | Office | 4,760 | 15 | $6.86 | $33K |
| J0587 Injection, rimabotulinumtoxinb, 100 units | Office | 2,315 | 20 | $10.21 | $24K |
| 99214 Office E&M - Established | Office | 623 | 277 | $96.21 | $60K |
| 99215 Office E&M - Established | Office | 197 | 136 | $141.81 | $28K |
| 99205 Office E&M - New | Office | 110 | 110 | $159.24 | $18K |
| 64612 Musculoskeletal | Office | 76 | 26 | $151.20 | $11K |
| 95874 Musculoskeletal | Office | 74 | 27 | $59.71 | $4,418 |
| 11105 Skin Biopsy | Office | 68 | 34 | $48.20 | $3,278 |
| 95970 Electrical Nerve Conductivity | Office | 44 | 28 | $15.22 | $670 |
| 96132 Behavioral Health Services | Office | 43 | 43 | $105.71 | $4,546 |
| 64616 Musculoskeletal | Office | 42 | 16 | $132.96 | $5,584 |
| 96136 Behavioral Health Services | Office | 42 | 42 | $33.74 | $1,417 |
| 95984 Electrical Nerve Conductivity | Office | 38 | 14 | $33.42 | $1,270 |
| 95816 Neurologic | Office | 37 | 36 | $308.90 | $11K |
| 11104 Skin Biopsy | Office | 34 | 34 | $94.49 | $3,213 |
By year: 2022 $243K for 15,409 services; 2023 $238K for 13,738 services; 2024 $244K for 12,530 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ramon A Gil prescribed most often to Medicare patients was Rytary (Carbidopa/Levodopa), with 651 prescriptions and refills. In total Ramon A Gil wrote 2,553 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rytary Carbidopa/Levodopa | 651 | 1,502 | 155 | $1.2M |
| Clozapine Generic | 270 | 270 | 21 | $3,141 |
| Gocovri Amantadine Hcl | 156 | 217 | 23 | $525K |
| Primidone Generic | 137 | 385 | 44 | $4,736 |
| Rasagiline Mesylate Generic | 112 | 312 | 38 | $27K |
| Nuplazid Pimavanserin Tartrate | 100 | 130 | 18 | $615K |
| Droxidopa Generic | 84 | 117 | 13 | $385K |
| Donepezil Hcl Generic | 76 | 220 | 30 | $995 |
| Ongentys Opicapone | 66 | 112 | 18 | $73K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 65 | 185 | 29 | $1,674 |
| Clonazepam Generic | 61 | 81 | 19 | $448 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 61 | 151 | 22 | $1,434 |
| Rivastigmine Generic | 59 | 131 | 22 | $18K |
| Rexulti Brexpiprazole | 34 | 50 | Under 11 | $71K |
| Folic Acid Generic | 34 | 100 | 12 | $478 |
Brand drugs: 1,285 claims; generic drugs: 1,268 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ramon A Gil $85K ($85K in general payments such as food, travel and fees) from 16 companies. The largest payer was Neurocrine BioSciences, Inc. with $35K.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 42 | $35K |
| MDD US Operations, LLC | 56 | $30K |
| Amneal Pharmaceuticals LLC AMRX | 15 | $10K |
| Abbott Laboratories ABT | 12 | $8,200 |
| Eisai Inc. 4523.T | 9 | $393 |
| Boston Scientific Corporation BSX | 4 | $246 |
| Medtronic, Inc. MDT | 1 | $161 |
| Inspire Medical Systems, Inc. INSP | 1 | $158 |
| Axsome Therapeutics, Inc. AXSM | 1 | $104 |
| Lilly USA, LLC LLY | 5 | $103 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.